[go: up one dir, main page]

PL2068938T3 - Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI - Google Patents

Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI

Info

Publication number
PL2068938T3
PL2068938T3 PL07842842T PL07842842T PL2068938T3 PL 2068938 T3 PL2068938 T3 PL 2068938T3 PL 07842842 T PL07842842 T PL 07842842T PL 07842842 T PL07842842 T PL 07842842T PL 2068938 T3 PL2068938 T3 PL 2068938T3
Authority
PL
Poland
Prior art keywords
leukemia
tyrosine kinase
abl tyrosine
cmin
kinase inhibitor
Prior art date
Application number
PL07842842T
Other languages
English (en)
Inventor
Insa Gathmann
Francois-Xavier Mahon
Mathieu Molimard
Stéphane Picard
Yanfeng Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39092883&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2068938(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2068938T3 publication Critical patent/PL2068938T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Ecology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL07842842T 2006-09-22 2007-09-20 Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI PL2068938T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82662206P 2006-09-22 2006-09-22
US82827806P 2006-10-05 2006-10-05
PCT/US2007/078978 WO2008036792A2 (en) 2006-09-22 2007-09-20 Method of optimizing the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitors
EP07842842A EP2068938B1 (en) 2006-09-22 2007-09-20 Optimization of the treatment of philadelphia-positive leukemia with abl tyrosine kinase inhibitor imatinib

Publications (1)

Publication Number Publication Date
PL2068938T3 true PL2068938T3 (pl) 2011-06-30

Family

ID=39092883

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07842842T PL2068938T3 (pl) 2006-09-22 2007-09-20 Optymalizacja leczenia białaczki z chromosomem Philadelphia imatinibem będącym inhibitorem kinazy tyrozynowej AbI

Country Status (24)

Country Link
US (2) US20090281113A1 (pl)
EP (2) EP2251042A3 (pl)
JP (1) JP5735742B2 (pl)
KR (1) KR20090065512A (pl)
AT (1) ATE495761T1 (pl)
AU (1) AU2007299764B2 (pl)
BR (1) BRPI0717099A2 (pl)
CA (1) CA2662977A1 (pl)
CL (1) CL2007002725A1 (pl)
CY (1) CY1111356T1 (pl)
DE (1) DE602007012122D1 (pl)
DK (1) DK2068938T3 (pl)
HR (1) HRP20110250T1 (pl)
IL (1) IL197296A (pl)
MA (1) MA30786B1 (pl)
MX (1) MX2009003082A (pl)
NO (1) NO20091490L (pl)
NZ (1) NZ575113A (pl)
PL (1) PL2068938T3 (pl)
PT (1) PT2068938E (pl)
TN (1) TN2009000094A1 (pl)
TW (1) TWI398251B (pl)
WO (1) WO2008036792A2 (pl)
ZA (1) ZA200901220B (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526537T3 (es) 2008-01-23 2015-01-13 Novartis Ag Método para optimizar con imatinib el tratamiento de enfermedades proliferativas mediadas por el receptor kit de tirosina quinasa
WO2010065433A1 (en) 2008-12-01 2010-06-10 Novartis Ag Method of optimizing the treatment of philadelphia-positive leukemia with imatinib mesylate
US20110046919A1 (en) 2009-03-02 2011-02-24 Juliesta Elaine Sylvester Method for accurate measurement of enzyme activities
FR2943418A1 (fr) * 2009-03-17 2010-09-24 Centre Nat Rech Scient Procedes de mesure de la quantite intracellulaire de molecules d'interet intrinsequement fluorescentes par cytometrie en flux et leurs applications
JPWO2015076213A1 (ja) * 2013-11-22 2017-03-16 国立研究開発法人国立成育医療研究センター 急性リンパ芽球性白血病の新規キメラ遺伝子ａｔｆ７ｉｐ−ｐｄｇｆｒｂ
US9683220B2 (en) * 2015-07-07 2017-06-20 Codexis, Inc. P450-BM3 variants with improved activity
IT201900008808A1 (it) 2019-06-13 2020-12-13 Univ Ca Foscari Metodo per la determinazione della concentrazione di 4-[(4-metil-1-piperazinil)metil]-n-(4-metil-3-{[4-(3-piridinil)-2-pirimidinil]-ammino}fenil)benzammide(imatinib) in campioni di plasma
CN114994213A (zh) * 2022-06-28 2022-09-02 北京赛诺浦生物技术有限公司 一种测定人血浆中抗肿瘤药物酪氨酸激酶抑制血药浓度的试剂盒及测定方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
ID30460A (id) 1999-04-15 2001-12-06 Bristol Myers Squibb Co Inhibitor-inhibitor protein siklik tirosin kinase
GB0202873D0 (en) 2002-02-07 2002-03-27 Novartis Ag Organic compounds
AU2003227639A1 (en) * 2002-04-17 2003-10-27 Novartis Ag Methods to predict patient responsiveness to tyrosine kinase inhibitors
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
RU2401265C2 (ru) 2004-06-10 2010-10-10 Айрм Ллк Соединения и композиции в качестве ингибиторов протеинкиназы
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
MY148074A (en) 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant

Also Published As

Publication number Publication date
MX2009003082A (es) 2009-04-01
RU2009114856A (ru) 2010-10-27
EP2251042A2 (en) 2010-11-17
IL197296A0 (en) 2011-08-01
US20170007605A1 (en) 2017-01-12
DE602007012122D1 (de) 2011-03-03
EP2251042A3 (en) 2012-05-02
JP5735742B2 (ja) 2015-06-17
DK2068938T3 (da) 2011-04-04
BRPI0717099A2 (pt) 2013-10-15
ATE495761T1 (de) 2011-02-15
NZ575113A (en) 2012-03-30
TW200822926A (en) 2008-06-01
CL2007002725A1 (es) 2008-05-16
AU2007299764B2 (en) 2011-10-13
HRP20110250T1 (hr) 2011-05-31
EP2068938B1 (en) 2011-01-19
IL197296A (en) 2011-11-30
MA30786B1 (fr) 2009-10-01
KR20090065512A (ko) 2009-06-22
CA2662977A1 (en) 2008-03-27
EP2068938A2 (en) 2009-06-17
AU2007299764A1 (en) 2008-03-27
NO20091490L (no) 2009-06-15
CY1111356T1 (el) 2015-08-05
PT2068938E (pt) 2011-03-23
WO2008036792A2 (en) 2008-03-27
WO2008036792A3 (en) 2008-11-13
JP2010504353A (ja) 2010-02-12
US20090281113A1 (en) 2009-11-12
TWI398251B (zh) 2013-06-11
ZA200901220B (en) 2010-02-24
HK1133194A1 (en) 2010-03-19
TN2009000094A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
CY1111356T1 (el) Βελτιστοποιηση της θεραπειας της θετικης στο χρωμοσωμα της φιλαδελφειας λευχαιμιας με ιματινιμπη, εναν αναστολεα κινασης τυροσινης toy abl
Cappuzzo et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC)
Pfingst et al. Importance of cochlear health for implant function
EA201690111A1 (ru) Имидазопиразиновые ингибиторы тирозинкиназы syk
RU2015104058A (ru) ОПРЕДЕЛЕНИЕ ЧУВСТВИТЕЛЬНОСТИ КЛЕТОК К ОБРАБОТКЕ ИНГИБИТОРОМ B-Raf ПУТЕМ ДЕТЕКЦИИ МУТАЦИИ KRAS И УРОВНЕЙ ЭКСПРЕССИИ RTK
BR0311814A (pt) Método de tratar câncer empregando inibidores de cinase
EA200600920A1 (ru) Иммуносорбентные исследования крови для оценки пароксизмальных церебральных разрядов
KR20220108201A (ko) 수면 개선 방법
BRPI0518795A2 (pt) mÉtodos para determinar a eficÁcia de um tratamento terapÊutico anti-inflamatàrio de um indivÍduo e para selecionar um indivÍduo que sofre de uma certa doenÇa inflamatària para receber tratamento terapÊutico anti-inflamatàrio
WO2010066891A3 (en) Method for predicting the response to treatment by tyrosine kinase inhibitors targeting the bcr-abl fusion protein in chronic myeloid leukaemia patients
RU2020134183A (ru) Способ ингибирования пути egf/egfr в комбинации с ингибиторами тирозинкиназы
RU2010101634A (ru) Способ оптимизации лечения хронического миелолейкоза с помощью ингибиторов трирозинкиназы abi
DK1843757T3 (da) Behandling af fantomfænomener
WO2009061847A3 (en) Methods for diagnosing and treating pelvic pain disorders via beta-catenin
CN115175678B (zh) 使用btk抑制剂及其组合治疗dlbcl的方法
EA201300410A1 (ru) Стратификация страдающих раком пациентов по чувствительности к терапии с использованием ингибиторов ptk2
US8697702B2 (en) Method of optimizing the treatment of Philadelphia-positive leukemia with imatinib mesylate
TW200507828A (en) Method for treatment of chemotherapy-induced diarrhea
Büchner et al. Two years of experience using stimulation rates between 800 and 5000 pps with the clarion CII implant
Pianka et al. GENE-38. IDH1MUT INDUCES N6-METHYLADENOSINE (m6A) RNA HYPERMETHYLATION VIA D-2-HG IN GLIOMA
CN102526734A (zh) 治疗年龄相关性听力损失的药物组合物及其应用
Rodriguez et al. AB0165 THE ROLE OF CXCL4, CXCL8 AND GDF-15 IN SYSTEMIC SCLEROSIS
ATE312612T1 (de) Methode zur optimierung der verwendung von 6- mercaptopurin in der behandlung von immun- vermittelten gastrointestinalen störungen
Gu The effect of obstructive sleep apnea on sleep architecture and cognition in Parkinson’s disease
WO2001045690A3 (en) Use of bvdu for inhibiting the growth of hyperproliferative cells